What Researchers Did
Researchers reviewed the characteristics, incidence, and treatments of early complications occurring within 100 days after haematopoietic stem cell transplantation in children.
What They Found
They found that veno-occlusive disease (VOD) occurs in 27-40% of children, with a mortality rate of 20-50%, and is effectively treated with defibrotide. Thrombotic microangiopathy (TAM) has an incidence of 4-13%, often associated with immunosuppressants, and is managed with plasmapheresis and supportive care. Engraftment syndrome, characterized by fever and respiratory issues, is treated with steroids.
What This Means for Canadian Patients
Understanding the early complications like VOD, TAM, and engraftment syndrome following paediatric HSCT can help Canadian clinicians with timely diagnosis and intervention. This knowledge can improve patient outcomes by guiding appropriate treatments such as defibrotide for VOD or steroids for engraftment syndrome.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or by Canadian researchers.
Study Limitations
As a review of existing literature, this study's findings are limited by the scope and quality of previously published research.